ECOG-ACRIN Cancer Research Group
@eaonc.bsky.social
Biomarker-driven medical research involving adults who have or are at risk of developing cancer
EA is hosting a webinar on EA1241, a companion study for pts previously enrolled in TAILORx or RxPONDER. Investigators & #ClinicalResearch professionals are invited to register below.
📅Feb 4 | 4 PM ET
🎙 Joseph Sparano, MD, Kevin Kalinsky, MD, MS, & Rima Patel, MD
🔗https://bit.ly/EA1241webinar
📅Feb 4 | 4 PM ET
🎙 Joseph Sparano, MD, Kevin Kalinsky, MD, MS, & Rima Patel, MD
🔗https://bit.ly/EA1241webinar
January 16, 2026 at 2:37 PM
EA is hosting a webinar on EA1241, a companion study for pts previously enrolled in TAILORx or RxPONDER. Investigators & #ClinicalResearch professionals are invited to register below.
📅Feb 4 | 4 PM ET
🎙 Joseph Sparano, MD, Kevin Kalinsky, MD, MS, & Rima Patel, MD
🔗https://bit.ly/EA1241webinar
📅Feb 4 | 4 PM ET
🎙 Joseph Sparano, MD, Kevin Kalinsky, MD, MS, & Rima Patel, MD
🔗https://bit.ly/EA1241webinar
DYK funding for NIH and NCI ends on 1/30? Act now & ask Congress to support sustainable, long-term funding for biomedical & #CancerResearch for FY26: bit.ly/3LpZJau
Federal Funding for Cancer Research
As Congress negotiates Fiscal Year 2025 appropriations bills, urge them to make cancer research a top priority.
bit.ly
January 13, 2026 at 3:10 PM
DYK funding for NIH and NCI ends on 1/30? Act now & ask Congress to support sustainable, long-term funding for biomedical & #CancerResearch for FY26: bit.ly/3LpZJau
“This is a great time to be in hashtag#oncology” — and also a time to rebuild how we support hashtag#science, access, & policy, says Dr. Otis Brawley, chair of our Social Determinants of Health Working Group. Catch his reflections in The Cancer Letter: bit.ly/4pgVzPX #SciencePolicy #SDOH
Otis Brawley looks back on a year of great science and greater challenges - The Cancer Letter
In a year that brought us new KRAS-inhibiting drugs, deepened our understanding of HER2 in breast cancer, and highlighted new potential for mRNA vaccines, the cancer field was also rocked by uncertain...
bit.ly
January 7, 2026 at 6:29 PM
“This is a great time to be in hashtag#oncology” — and also a time to rebuild how we support hashtag#science, access, & policy, says Dr. Otis Brawley, chair of our Social Determinants of Health Working Group. Catch his reflections in The Cancer Letter: bit.ly/4pgVzPX #SciencePolicy #SDOH
#FindingsFriday: Don’t miss the newest round-up of recently presented findings from ECOG-ACRIN Cancer Research Group & PrECOG Cancer Research Group #ClinicalTrials. See key #CancerResearch results and why they matter: bit.ly/3YI9raZ #BreastCancer #Leukemia #Lymphoma
December 2025 Research Round-Up
Read about the latest clinical trial findings in breast cancer, hematology research, precision medicine, and PrECOG studies.
bit.ly
December 26, 2025 at 2:27 PM
#FindingsFriday: Don’t miss the newest round-up of recently presented findings from ECOG-ACRIN Cancer Research Group & PrECOG Cancer Research Group #ClinicalTrials. See key #CancerResearch results and why they matter: bit.ly/3YI9raZ #BreastCancer #Leukemia #Lymphoma
What happens when #ResearchFunding slows? A new analysis looks at stalled studies, delayed discoveries, and the challenges researchers face navigating uncertainty. Read more: bit.ly/44FKmRI #NIH
What I’ve learned by mapping the impacts of NIH cuts
The co-founder of SCIMaP looks at the year of NIH cuts — and what they say about the future of American research.
bit.ly
December 24, 2025 at 3:52 PM
What happens when #ResearchFunding slows? A new analysis looks at stalled studies, delayed discoveries, and the challenges researchers face navigating uncertainty. Read more: bit.ly/44FKmRI #NIH
ICYMI: Watch Joseph A. Sparano, MD, FACP discuss initial findings from a public-private partnership between ECOG-ACRIN & Caris Life Sciences to improve recurrence risk assessment in early-stage #BreastCancer using #ArtificialIntelligence. Video via MedPage Today: bit.ly/48R3uNN #bcsm #AI #SABCS25
AI Model Improves Prediction of Early and Late Breast Cancer Recurrence
Joseph A. Sparano details multimodal approach outperforming the 21-gene recurrence score
bit.ly
December 18, 2025 at 6:26 PM
ICYMI: Watch Joseph A. Sparano, MD, FACP discuss initial findings from a public-private partnership between ECOG-ACRIN & Caris Life Sciences to improve recurrence risk assessment in early-stage #BreastCancer using #ArtificialIntelligence. Video via MedPage Today: bit.ly/48R3uNN #bcsm #AI #SABCS25
Support for collaborative, federally funded #CancerResearch remains essential. The NCI Director Dr. Tony Letai shares his perspective on sustaining this work in a conversation with The Cancer Letter. Read the interview: bit.ly/3Mzqnhd
Anthony Letai pledges to ensure stability for extramural and intramural cancer science - The Cancer Letter
Stepping into the NCI director’s job at the end of a nerve-racking year, Anthony Letai wants you to know that the federal government is not going out of the business of cancer research. To access this...
bit.ly
December 16, 2025 at 2:35 PM
Support for collaborative, federally funded #CancerResearch remains essential. The NCI Director Dr. Tony Letai shares his perspective on sustaining this work in a conversation with The Cancer Letter. Read the interview: bit.ly/3Mzqnhd
Reposted by ECOG-ACRIN Cancer Research Group
ECOG-ACRIN, Caris present breast cancer recurrence and risk stratification AI tools (@eaonc.bsky.social)
https://cancerletter.com/clinical-roundup/20251212_6a/
https://cancerletter.com/clinical-roundup/20251212_6a/
ECOG-ACRIN, Caris present breast cancer recurrence and risk stratification AI tools - The Cancer Letter
Researchers have presented the initial findings from a major multi-year collaboration between the ECOG-ACRIN Cancer Research Group and Caris Life Sciences focused on transforming recurrence risk assessment in early-stage breast cancer through artificial intelligence. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login or […]
cancerletter.com
December 15, 2025 at 4:30 PM
ECOG-ACRIN, Caris present breast cancer recurrence and risk stratification AI tools (@eaonc.bsky.social)
https://cancerletter.com/clinical-roundup/20251212_6a/
https://cancerletter.com/clinical-roundup/20251212_6a/
Attending #SABCS25 this week? View this helpful guide to
@eaonc.bsky.social research at the meeting, including data from an exciting TAILORx correlative science initiative. More: bit.ly/4iTDohN #BreastCancer #bcsm
@eaonc.bsky.social research at the meeting, including data from an exciting TAILORx correlative science initiative. More: bit.ly/4iTDohN #BreastCancer #bcsm
Guide to SABCS 2025: ECOG-ACRIN research at the world’s largest breast cancer conference
Learn about the multiple breast cancer research discoveries made by the group that will be included at the 2025 San Antonio Breast Cancer Symposium
bit.ly
December 10, 2025 at 6:54 PM
Attending #SABCS25 this week? View this helpful guide to
@eaonc.bsky.social research at the meeting, including data from an exciting TAILORx correlative science initiative. More: bit.ly/4iTDohN #BreastCancer #bcsm
@eaonc.bsky.social research at the meeting, including data from an exciting TAILORx correlative science initiative. More: bit.ly/4iTDohN #BreastCancer #bcsm
New analysis of 10 ECOG-ACRIN Cancer Research Group trials shows that for Black #AML patients, survival advantage typically linked to certain mutations (like NPM1) doesn’t hold—highlighting a need to rethink how genetic risk factors are applied across racial groups. More: bit.ly/4pqT92h #ASH25
Black Patients With AML Face Lower Survival Outcomes | CURE
Race has been identified as an independent prognostic factor in patients with AML receiving intensive chemotherapy.
bit.ly
December 9, 2025 at 7:28 PM
New analysis of 10 ECOG-ACRIN Cancer Research Group trials shows that for Black #AML patients, survival advantage typically linked to certain mutations (like NPM1) doesn’t hold—highlighting a need to rethink how genetic risk factors are applied across racial groups. More: bit.ly/4pqT92h #ASH25
Attending #ASH25 this weekend? Don't miss the initial results from the myeloMATCH #PrecisionMedicine trial. More info on these exciting updates can be found here: dctd.cancer.gov/about/news-e...
MyeloMATCH Presentations at ASH 2025
NCI's presentations on MyeloMATCH at the 2025 American Society of Hematology Annual Meeting
dctd.cancer.gov
December 5, 2025 at 7:14 PM
Attending #ASH25 this weekend? Don't miss the initial results from the myeloMATCH #PrecisionMedicine trial. More info on these exciting updates can be found here: dctd.cancer.gov/about/news-e...
#FindingsFriday: A new analysis of E3805/CHAARTED by Abhishek Tripathi, MD & colleagues shows long-term outcomes for men with metastatic #ProstateCancer may be tied to PSA levels early in treatment. Could offer hope and better planning. More: bit.ly/4oL80n7
Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial☆
The CHAARTED trial investigated the long-term survival of patients with metastatic
hormone-sensitive prostate cancer (HSPC) treated with androgen deprivation therapy
(ADT) with or without docetaxel (T...
bit.ly
December 5, 2025 at 2:37 PM
#FindingsFriday: A new analysis of E3805/CHAARTED by Abhishek Tripathi, MD & colleagues shows long-term outcomes for men with metastatic #ProstateCancer may be tied to PSA levels early in treatment. Could offer hope and better planning. More: bit.ly/4oL80n7
At #ASH2025, ECOG-ACRIN & @precogonc.bsky.social researchers will present data that could improve treatments for #AML, #ALL, #MCL, #CLL and more. View our full guide to the meeting: bit.ly/4rtkbHp #BloodCancer #leukemia #lymphoma
Guide to ASH 2025: ECOG-ACRIN and PrECOG are set to reveal multiple blood cancer research discoveries
Lear more about the 11 in-depth scientific analyses aim to enhance the precision and safety of treatments for hematologic malignancies.
bit.ly
December 4, 2025 at 9:09 PM
At #ASH2025, ECOG-ACRIN & @precogonc.bsky.social researchers will present data that could improve treatments for #AML, #ALL, #MCL, #CLL and more. View our full guide to the meeting: bit.ly/4rtkbHp #BloodCancer #leukemia #lymphoma
Reposted by ECOG-ACRIN Cancer Research Group
The NCI myeloMATCH precision medicine trial portfolio in myeloid cancers is highlighted in numerous presentations at the upcoming #ASH25 meeting. Learn more:
dctd.cancer.gov/about/news-e...
@swog.org @eaonc.bsky.social @cctg.bsky.social #NCORP
dctd.cancer.gov/about/news-e...
@swog.org @eaonc.bsky.social @cctg.bsky.social #NCORP
December 1, 2025 at 1:46 PM
The NCI myeloMATCH precision medicine trial portfolio in myeloid cancers is highlighted in numerous presentations at the upcoming #ASH25 meeting. Learn more:
dctd.cancer.gov/about/news-e...
@swog.org @eaonc.bsky.social @cctg.bsky.social #NCORP
dctd.cancer.gov/about/news-e...
@swog.org @eaonc.bsky.social @cctg.bsky.social #NCORP
On #WorldPancreaticCancerDay 💜 we are shining a light on two @eaonc.bsky.social clinical trials aiming to improve outcomes for patients with #PancreaticCancer & #PancreaticCysts - EA2185 and EA2192/APOLLO. Learn more here 👉 bit.ly/pancreaticf25
Ongoing Trials: A closer look at ECOG-ACRIN’s clinical trials for patients with pancreatic conditions
For Pancreatic Cancer Awareness Month, we highlight two actively recruiting clinical trials for patients with pancreatic conditions
bit.ly
November 20, 2025 at 4:51 PM
On #WorldPancreaticCancerDay 💜 we are shining a light on two @eaonc.bsky.social clinical trials aiming to improve outcomes for patients with #PancreaticCancer & #PancreaticCysts - EA2185 and EA2192/APOLLO. Learn more here 👉 bit.ly/pancreaticf25
Can patients with high-risk retroperitoneal #sarcoma benefit from neoadjuvant chemotherapy? The international EA7211/STRASS 2 #ClinicalTrial, led in the US by Dr. Kenneth Cardona, aims to find out. More: bit.ly/EA7211 #leiomyosarcoma #liposarcoma
November 17, 2025 at 6:29 PM
Can patients with high-risk retroperitoneal #sarcoma benefit from neoadjuvant chemotherapy? The international EA7211/STRASS 2 #ClinicalTrial, led in the US by Dr. Kenneth Cardona, aims to find out. More: bit.ly/EA7211 #leiomyosarcoma #liposarcoma
#FindingsFriday: New insights from the CHAARTED trial, presented at #ASTRO25 - the APUC-6 signature (six androgen production/uptake & conversion genes) may help stratify metastatic #ProstateCancer & refine treatment response. Learn more: bit.ly/43SaV5t #PrecisionMedicine
Validating the APUC-6 Signature in mHSPC from the ECOG-ACRIN E3805 CHAARTED Trial - Xiaolei Shi
UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
bit.ly
November 14, 2025 at 4:47 PM
#FindingsFriday: New insights from the CHAARTED trial, presented at #ASTRO25 - the APUC-6 signature (six androgen production/uptake & conversion genes) may help stratify metastatic #ProstateCancer & refine treatment response. Learn more: bit.ly/43SaV5t #PrecisionMedicine
ICYMI, fascinating finding from #ESMO2025: patients with #cancer who received mRNA COVID vaccines soon after starting #immunotherapy showed stronger immune responses & improved survival. Read the the publication in @nature.com: bit.ly/3LyoZuF #CancerResearch
SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade - Nature
mRNA vaccines targeting SARS-CoV-2 also sensitize tumours to immune checkpoint inhibitors.
bit.ly
November 13, 2025 at 6:03 PM
ICYMI, fascinating finding from #ESMO2025: patients with #cancer who received mRNA COVID vaccines soon after starting #immunotherapy showed stronger immune responses & improved survival. Read the the publication in @nature.com: bit.ly/3LyoZuF #CancerResearch
#FindingsFriday: ICYMI, at #ESMO25 Dr. Janice Mehnert @nyulangone.bsky.social presented results from the STAMP trial, showing that giving pembro after surgery may help prevent #MerkelCellCarcinoma from spreading to distant organs. Promising progress for this rare #SkinCancer! More: bit.ly/49uM4sa
Press Release: Immunotherapy after surgery shows potential in preventing the spread of aggressive skin cancer
A new clinical trials shows that pembrolizumab, a drug that utilizes the body’s immune system to target and eliminate cancer cells, appeared to reduce the risk of distant metastases for an aggressive ...
bit.ly
November 7, 2025 at 1:47 PM
#FindingsFriday: ICYMI, at #ESMO25 Dr. Janice Mehnert @nyulangone.bsky.social presented results from the STAMP trial, showing that giving pembro after surgery may help prevent #MerkelCellCarcinoma from spreading to distant organs. Promising progress for this rare #SkinCancer! More: bit.ly/49uM4sa
The recently reported DREAM3R results show that, for pts w/ pleural #mesothelioma, the addition of durvalumab to chemo = higher tumor response—yet survival benefit is unclear. More research is needed. Read about this collab between @precogonc.bsky.social & @togaanz.bsky.social: bit.ly/47Pw02S
Durvalumab Plus Chemo Yields Inconclusive Results in Advanced Pleural Mesothelioma | OncLive
Durvalumab in combination with chemotherapy produced outcomes consistent with prior studies in patients with advanced pleural mesothelioma.
bit.ly
November 6, 2025 at 3:29 PM
The recently reported DREAM3R results show that, for pts w/ pleural #mesothelioma, the addition of durvalumab to chemo = higher tumor response—yet survival benefit is unclear. More research is needed. Read about this collab between @precogonc.bsky.social & @togaanz.bsky.social: bit.ly/47Pw02S
After being diagnosed with #PancreaticCancer, Steven Merlin found hope through a #clinicaltrial. Now as an ECOG-ACRIN advocate, he shares his perspective on the benefits of clinical trials. Read his inspiring story: bit.ly/beatingtheod...
Beating the odds: Steven Merlin’s journey through pancreatic cancer and clinical trials
An inspiring interview with a 13-year survivor of stage 4 pancreas cancer
bit.ly
November 5, 2025 at 7:21 PM
After being diagnosed with #PancreaticCancer, Steven Merlin found hope through a #clinicaltrial. Now as an ECOG-ACRIN advocate, he shares his perspective on the benefits of clinical trials. Read his inspiring story: bit.ly/beatingtheod...
DYK only 17% of US cancer trials are federally funded—yet they’re far more likely to study rare cancers, pediatric cancers, & multimodality treatments? Public funding = innovation where it’s needed most. More: bit.ly/47kYNME #Oncology #CancerResearch @swog.org
Study Finds Federally Funded Clinical Trials Play a Vital Role in Cancer Research, Especially for Rare and Pediatric Cancers
Although industry-sponsored cancer clinical trials often focus on single-agent drug trials, federally funded cancer clinical trials are more likely to investigate drug combinations with other treatmen...
bit.ly
November 5, 2025 at 2:10 PM
DYK only 17% of US cancer trials are federally funded—yet they’re far more likely to study rare cancers, pediatric cancers, & multimodality treatments? Public funding = innovation where it’s needed most. More: bit.ly/47kYNME #Oncology #CancerResearch @swog.org
The Fall 2025 Group Meeting session recordings are now available on the Attendee Hub Website.
Simply log in with your first name, last name, and the email address you used during registration ➡️ cvent.me/EvkYal #EAOnc
Simply log in with your first name, last name, and the email address you used during registration ➡️ cvent.me/EvkYal #EAOnc
October 29, 2025 at 6:40 PM
The Fall 2025 Group Meeting session recordings are now available on the Attendee Hub Website.
Simply log in with your first name, last name, and the email address you used during registration ➡️ cvent.me/EvkYal #EAOnc
Simply log in with your first name, last name, and the email address you used during registration ➡️ cvent.me/EvkYal #EAOnc
Phase 3 #ClinicalTrial EA8231 is now enrolling! This study is exploring a new treatment approach for patients with treatment-refractory locally-advanced or metastatic #UrothelialCancer. Learn more: bit.ly/ea8231-study... #TargetedTherapy
Now Enrolling: EA8231 Study for Patients With Bladder Cancer That Has Progressed Following Treatment
This phase 3 clinical trial is testing a new treatment approach for patients with treatment-refractory locally-advanced or metastatic urothelial cancer
bit.ly
October 23, 2025 at 5:11 PM
Phase 3 #ClinicalTrial EA8231 is now enrolling! This study is exploring a new treatment approach for patients with treatment-refractory locally-advanced or metastatic #UrothelialCancer. Learn more: bit.ly/ea8231-study... #TargetedTherapy
Day 2 of the #EAOnc Fall 2025 Group Meeting is underway! Let us know which sessions you are heading to today. And don’t miss our General Session at 5:30 PM! 🩺🩻📈
October 23, 2025 at 2:20 PM
Day 2 of the #EAOnc Fall 2025 Group Meeting is underway! Let us know which sessions you are heading to today. And don’t miss our General Session at 5:30 PM! 🩺🩻📈